2023 ESC Guidelines for the management of cardiomyopathiesElena Arbelo, Ulf Landmesser, Alexandros Protonotarios et al.|European Heart Journal|2023Cited by 2.3k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Amos Katz, Miloš Kubánek et al.|The Lancet|2020Cited by 1.2k
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fractionEsther González-López, Pablo García‐Pavía, María Gallego‐Delgado et al.|European Heart Journal|2015Cited by 1.1k
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial DiseasesPablo García‐Pavía, Aleš Linhart, Claudio Rapezzi et al.|European Heart Journal|2021Cited by 1.1k
Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic CardiomyopathiesMartín Ortiz-Genga, Lorenzo Monserrat, Sofía Cuenca et al.|Journal of the American College of Cardiology|2016Cited by 472